HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.

Trial Details

NCT ID
NCT06515314
Phase
PHASE1
Sponsor
Shanghai Ruiliyuan Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • AFP Specific T Cell Receptor T Cells
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • The patient must be willing to sign the informed consent form.
  • Age ≥18 years and ≤75 years.
  • HLA-A 02:03 allele positive
  • Histologically-confirmed AFP positive hepatocellular carcinoma (HCC) or other solid tumor, No benefits from curative surgery or other local therapi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →